natgillin/translations-raw huggingface dataset:
Use of an ActRIIa-Fc fusion protein for the manufacture of a medicament for treatment or prevention of multiple myeloma in a human patient, wherein the ActRIIa-Fc fusion protein is as defined in any one of claims 1 to 10. 
Uporaba ActRIla-Fc fuzijskog proteina, naznačena time, što se koristi za izradu lijeka za liječenje ili prevenciju multiplog mijeloma kod humanog pacijenta, pri čemu je ActRIIa-Fc fuzijski protein onakav kako je definirano u bilo kojem od zahtjeva 1 do 10.
Diluents can be selected from the group comprising of lactose, starch, dibasic calcium phosphate anhydrous, tribasic calcium phosphate, kaolin, sucrose, mannitol, precipitated calcium carbonate, sorbitol, maltodextrin, cellulose derivatives including powdered cellulose, micro crystalline cellulose and other materials known to one of ordinary skill in the art. 
Razrjeđivači mogu biti izabrani iz skupine koja obuhvaća laktozu, škrob, dibazični bezvodni kalcij fosfat, tribazični kalcij fosfat, kaolin, saharozu, manitol, istaloženi kalcij karbonat, sorbitol, maltodekstrin, derivate celuloze uključujući celulozu u prahu, mikro kristalnu celulozu i druge materijale poznate prosječnim stručnjacima.
Architecture system of a local grid (10) according to claim 1, characterised in that said Logic G is of self-configuration by the controller server of each single node and includes at least the following consequential Phases: 
Arhitektura sustava lokalne mreže (10) prema zahtjevu 1, naznačena time da je navedena Logika G samopodešavajuća putem poslužitelja kontrolera svakog pojedinog čvora i uključuje barem sljedeće značajne Faze, kao što je prikazano u odgovarajućem dijagramu (Slika 16):
The method according to claim 2, characterized by that at least one of the followings is used as sodium salt of saturated or unsaturated fatty acid: sodium palmitate, sodium oleate, sodium linoleate and sodium stearate. 
Metoda temeljem zahtjeva 2, naznačena time što se barem jedno od slijedećeg koristi kao natrijeva sol zasićene ili nezasićene masne kiseline: natrij palmitat, natrij oleat, natrij linoleat 1 natrij stearat.
The fabric according to claims 1, 3, 4 and 8, characterized in that said first inner breathable layer (211) is constituted by a diffusely macroperforated fabric. 
Tkanina u skladu s patentnim zahtjevima 1, 3, 41 8, naznačena time, da se navedeni prvi unutarnji prozračni sloj (211) sastoji od difuzno makroperforirane tkanine.
A compound of Claim 9, wherein R is selected from the group consisting of hydrogen, benzyl, 1-(4-methoxyphenyl)ethyl, methyl, 3-aminopropyl, and 2-methyl-2-morpholinopropyl. 
Spoj prema zahtjevu 9, naznačen time, da je R odabran iz skupine koju čine vodik, benzil, 1-(4-metoksifenil)etil, metil, 3-aminopropil i 2-metil-2-morfolinopropil.
A process for the synthesis of a compound of formula (I): 
Postupak za industrijsku sintezu spoja formule (I): a pe s dei S evi |
another protein inhibitor, such as one that inhibits the phosphoprotein (P) protein and/or large (L) protein; 
drugi inhibitor proteina, primjerice neki koji inhibira fosfoprotein (P) i/ili veliki (L) protein;
The reaction was cooled to room temperature and concentrated in vacuo. 
Reakcija se ohladi na sobnu temperaturu i koncentrira in vacuo.
In another aspect, the invention provides a method for the treatment of obesity, said method comprising the administration of a therapeutically effective amount of the crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I) together with pharmaceutically acceptable diluents or carriers, to said patient. 
U drugom aspektu, izum opisuje metodu liječenja pretilosti, gdje se navedena metoda sastoji od primjene terapijski učinkovite količine kristalnog 1-[3-[3-(4-klorfeniDpropoksilpropil]-piperidin monohidroklorida formule (1) zajedno s farmaceutski prihvatljivim razrjeđivačima, na navedenog pacijenta.
The compound according to claim 1 having Formula (II): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein: 
Spoj u skladu sa patentnim zahtjevom 1 koje ima Formulu (II): ili njegov stereoizomer, tautomer, ili farmaceutski prihvatljiva sol, pri čemu:
from a compound of the Formula VII: 
X iz spoja sa Formulom VII:
The chromatography profile is shown in FIG. 6 . 
Kromatografski profil je prikazan na Slici 6.
A polynucleotide comprising a nucleotide sequence encoding a polypeptide having a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen; and a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen; wherein the polypeptide binds to immobilized lysine. 
Polinukleotid koji sadrži nukleotidnu sekvence koja služi za enkodiranje polipeptida te sadrži jednu N-terminalnu kringl domenu koja je najmanje 90% istovjetna kringl 1 domeni nativnog ljudskog plazminogena; i C-terminalnu domenu koja je najmanje 90% istovjetna mjestu aktivacije i domeni serin proteaze ljudskog plazminogena, naznačen time da polipeptid veže u imobiliziranom lizinu i može biti aktiviran pomoću aktivatora plazminogena.
The antibody or an antigen-binding fragment for use of claim 3, wherein the agent is selected from the group consisting of a bisphosphonate, a parathyroid hormone, a parathyroid hormone analog, calcitonin, and a selective estrogen receptor modulator. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 19, naznačen time što je barem jedno terapeutsko sredstvo je odabrano iz skupine koju čine bisfosfonat, paratiroidni hormonski analog, kalcitonin, i selektivni modulator receptora estrogena (SERM).
The method of paragraph 17, wherein step (b) is performed within about 10 seconds and about 30 minutes after step (a). 
Postupak prema zahtjevu 16, naznačen time da se korak (b) provodi tijekom 10 sekundi do 30 minuta nakon koraka (a).
The process according to claim 4, where the reaction of a salt of compound of the formula (IV) with a base is performed in the same reaction mixture of claim 1 . 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se reakciju soli spoja formule (IV) s bazom provodi u istoj reakcijskoj smjesi u skladu patentnim zahtjevima 1-3.
The insertion of the spout into said inlet takes place before the container is filled. 
Umetanje ispusnog otvora u navedeni ulazni otvor događa se prije nego što se spremnik napuni.
the heavy chain Fv fragment of a monovalent Fab forming the antigen-binding domain is linked to one of the polypeptides forming the Fc domain via a CH1 domain and the light chain Fv fragment of the Fab is linked to a CL domain; and the light chain Fv fragment of the Fab forming the CD3-binding domain is linked to the other polypeptide forming the Fc domain via a CH1 domain and the heavy chain Fv fragment of the Fab is linked to a CL domain; 
Fv fragment teškog lanca jednovalentnog Fab koji tvori domenu za vezanje na antigen je vezan na jedan od polipeptida koji tvore Fc domenu preko domene CH1, a Fv fragment lakog lanca Fab je vezan na domenu CL; i Fv fragment lakog lanca Fab koji tvori domenu za vezanje na CD3 je vezan na drugi polipeptid koji tvori Fc domenu preko domene CH1, a Fv fragment teškog lanca Fab je vezan na domenu CL;
A gene encoding a protein of the following (i) or (ii), corresponding to an enzyme extractable fromplant bodies producing pyrethrin: 
Gen koji kodira protein temeljem (1) ili (11), odgovarajući enzimu koji se može dobiti 1z tijela biljaka koje proizvode Piretrin:
condensing the first vapor phase obtained in b) in the condenser to form a carbamate solution which is recycled to the reactor, 
kondenziranje prve parne faze dobivene u b) u kondenzatoru kako bi se dobila otopina karbamata koja se reciklira u reaktor
2-(6-(4-carbamoylphenyl)-5-methylpyridin-3-ylamino)-5-methylbenzoic acid and the pharmaceutically acceptable salts and N-oxides thereof. 
-(6-(4-karbamoilfenil)-5-metilpiridin-3-ilamino)-5-metilbenzojeva kiselina i farmaceutski prihvatljive soli i N-oksidi toga spoja.
According to another aspect of the present invention, there is provided a media insertion method in which programming is received by a programme receiver and may be output substantially immediately by the receiver and/or recorded at the receiver for subsequent output, the programming having a break defined therein such that media stored at the receiver may be selectively output during the break, wherein the media selection options differ between the break in output of the recorded programming and the break in output of the programming substantially immediately. 
Postupak umetanja medija u kojem programiranje prima prijemnik programa i emitira se uglavnom odmah putem prijemnika i/ili je snimljeno na prijemniku radi naknadnog emitiranja, pri čemu programiranje ima u njemu definiran prekid koji obuhvaća mnoštvo isječaka tako da se medij pohranjen u prijemniku selektivno emitira tijekom prekida, pri čemu programiranje koje prima prijemnik uključuje zamjenski raspored koji za svaki isječak identificira medij koji je moguće odabrati za emitiranje unutar navedenog isječka tijekom prekida, omogućavajući da se medij odabran za emitiranje pomoću prijemnika razlikuje od prekida izlaza snimljenog programiranja i prekida u uglavnom neposredno emitiranom programiranju.
A compound according to any one of claims 1 to 5 or stereoisomers or pharmaceutically acceptable salts thereof in combination with an anti-inflammatory, bronchodilatory, anti-histamine or anti-tussive drug substance, said compound and said drug substance being in the same or different pharmaceutical composition. 
Spoj prema bilo kojem od zahtjeva 1 do 5, ili njegovi stereoizomeri ili njegove farmaceutski prihvatljive soli, naznačen time, da se upotrebljava u kombinaciji s s anti-upalnom, bronhodilatornom, anti-histaminskom ili antitusivnom ljekovitom tvari, pri čemu su spomenuti spoj i spomenuta ljekovita tvar u istom ili u različitom farmaceutskom sastavu.
purifying the RV G protein in the form of micelles. 
(c) Pročišćavanje G proteina od virusa bjesnila (RV) u obliku micela.
R9', R9" and R9'" are independently selected from hydrogen and C1-3alkyl optionally substituted by hydroxyl, halo, C1-4alkoxy, carboxy or cyano); 
', R9" i R9'" su nezavisno odabrani od vodika i C1-3alkila opcionalno supstituirani sa hidroksilom, halo, C1-4alkoksi, karboksi ili cijano);
A compound of Claim 1, wherein Rb is selected from the group consisting of substituted phenyl, substituted pyridyl, substituted pyrimidinyl, substituted pyrazinyl, substituted indolyl, substituted thiazolyl, and substituted thienyl. 
Spoj prema zahtjevu 1, naznačen time, da Rb je odabran iz skupine koju čine supstituirani fenil, supstituirani piridil, supstituirani pirimidinil, supstituirani pirazinil, supstituirani indolil, supstituirani tiazolil i supstituirani tienil.
Compounds of formula (11) may be prepared from a compound of formula (111) wherein R6 is 2-hydroxyphenyl by reaction with carbonyldiimidazole or thiocarbonyidiimidazole in a suitable solvent such as dichloromethane and subsequent reaction of the product thus formed with aqueous acetone. 
Spojeve formule (11) može se dobiti iz spoja formule (111), gdje Ry je 2-hidroksifenil, reakcijom s karbonildiimidazolom ili tiokarbonildiimidazolom, u pogodnom otapalu, poput diklormetana, te naknadnom reakcijom tako dobivenog produkta s vodenom otopinom acetona,
A is a nonaromatic 4, 5, 6, 7, or 8-membered ring that contains 1 or 2 nitrogen atoms and, optionally, one sulfur or oxygen atom, wherein the nonaromatic ring is optionally substituted with 1,2, or 3 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, cyano, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, heteroaryl, heteroarylalkyl, hydroxy, hydroxyalkyl, nitro, NRCRD), (NRCRD)alkyl, (NRCRD)carbonyl, (NRCRD)carbonylalkyl, (NRCRD)sulfonyl, and oxo; and 
A je ne-aromatski 4, 5, 6, 7 ili 8-ero tlani prsten koji sadrži 1 ili 2 atoma dušika i po izboru, jedan atom sumpora ili kisika, pri čemu je ne-aromatski jprsten po izboru supstituran s 1, 2 ili 3 alkoksikarbonilom, alkoksikarbonilalkilom, alkilom, alkinilom, arilom, arilalkilom, cikloalkilom, cikloafkilalkilom, cijano, haloalkoksi, haloalkilom, halogenom, heterociklom, heterociklealkilom, heteroarilom, heteroarilalkilom, hidroksi, hidroksialkilom, nitro, NRcRop, (NReRp)alkilom, (NRcRp)karbonilom, (NRcRp)karbonilalkilom, (NRcRp) sulfonilom i okso; a Ra, Rs, Re i Ry su neovisno odabrani iz skupine koja se sastoji od vodika, alkila i alki karbonila.
The genetically modified dermal micro-organ of claim 2, wherein said dermal micro-organ includes most of the cross-section of the dermis. The genetically modified dermal micro-organ of claim 3, wherein said dermal micro-organ includes substantially the entire cross-section of the dermis. The genetically modified dermal micro-organ of any one of claims 1-3, wherein said dermal micro-organ further includes fat tissue. 
Genetički modificiran dermalni mikroorgan iz bilo kojeg od patentnih zahtjeva 1 - 2, naznačen time, da navedeni dermalni mikroorgan sadrži masno tkivo. Genetički modificiran dermalni mikroorgan iz bilo kojeg od patentnih zahtjeva 1 - 3, naznačen time, da je najmanje jedan navedeni rekombinantni genski produkt prirodno proizveden u organu iz kojeg dermalni mikroorgan potječe.
q is an integer ranging from 0 to 6; 
q je cijeli broj u rasponu od 0 do 6;
In one aspect the invention provides a combination as herein defined characterised in that the active ingredients (a) and (b) form part of a single pharmaceutical composition. 
Kombinacija sukladno bilo kojem prethodnom patentnom zahtjevu, naznačena time, da djelatni sastojci (a) i (b) čine jedinstveni farmaceutski pripravak.
a refinery system comprising a conversion unit to co-process a feedstock comprising a unenriched renewable fuel oil and a petroleum fraction in the presence of a catalyst; 
ko-procesiranje sirovine u prisutnosti katalizatora, gorivo sadrži proizvod fluidiziranog katalitičkog krekera koji ko-procesira sirovinu, navedena sirovina sadrži:
Start the stirrer on slow speed and add 2.1 kg of Orange Oil BP and 0.5 kg of Lemon Oil Ph. 
Uključiti mješalicu na sporu brzinu i dodati 2.1 kg narančinog ulja BP 1 0.5 kg limunovog ulja Ph.
A nanoparticle comprising the peptide of any one of aspects 1-10 and a cargo molecule. 
Nanočestica, koja sadrži peptid bilo kojeg patentnog zahtjeva 1-4 i molekulu tereta.
A capsule according to clause 21, wherein the height of the further ridge is larger than the height of the ridges. 
Kapsula (2) prema zahtjevu 21, naznačena time, da je visina dodatnog grebena (40) veća od visine grebena (28.i).
whereby a candidate substance that exhibits greater binding affinity to the activated HGF B chain than to the reference HGF B chain is selected as a substance that selectively binds activated HGF B chain. 
HGEF (5 lanac, pri čemu spomenuti usporedbeni f3 lanac u usporedbi s aktiviranim HGF (lancem ima smanjeno vezanje na c-met, prema čemu se tvar kandidat, koja pokazuje veći afinitet vezanja na aktivirani HGF (B lanac nego na usporedbeni HGEF (3 lanac, bira kao tvar koja selektivno veže aktivirani HGF (lanac.
The column was washed by 20 ml of PBS and the bound material was eluted with elution buffer containing 35% propylene glycol in 20 mM phosphate pH 8.4. 
Kolona je isprana sa 20 ml PBS-a i vezani je materijal eluiran sa puferom za eluaciju koji je sadržavao 35%-tni propilen glikol u 20 u fosfatu pH 8.4.
maintaining both the outflow of process air from the forming chamber and the inflow of process air into the forming chamber for a cooling time. 
- < održavanje oba toka, istjecanja zraka za postupak iz komore za oblikovanje (1) i utjecanja zraka za postupak u komoru za oblikovanje (1) za vrijeme hlađenja.
moistening the pre-mix with the granulation liquid and subsequently granulating the moistened pre-mix; 
vlaženje pre-smjese smjese s tekućinom za granulaciju i neposredno zatim granuliranje navlažene pre-smjese;
p is 0, 1 or 2; and x is an integer from 0 to 5. 
p je 0, 1 ili 2; i x je cijeli broj od 0 do 5.
is H or CH3; R2 is H or CH3; R3 is nitrogen protecting group; and one of R4 and R5 is H, and the other is -CH2-X, wherein X is phenyl or heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; each optionally substituted with from 1-3 substituents independently selected from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R')R'. 
Ri je H ili CH3; R> je H ili CH;; Rs je skupina koja štiti dušik; 1 jedan od Ry 1 Rs je H, 1 drugi je -CH2-X, pri čemu X je fenil ili heteroaril uključujući od 5 do 6 atoma prstena pri čemu su 1, 2, ili 3 od atoma prstena neovisno odabrani od skupine koja se sastoji od N, NH, N(C,-C; alkila), O 1 S; pri čemu je svaki izborno supstituiran s od 1-3 supstituenata neovisno odabranih od skupine koja se sastoji od halogena, cijano, Ci-Cg alkila, hidroksila, C,-C4 alkoksi i -N(R')R';
it comprises at least 20% more charged N-glycosidically linked carbohydrate chains of the total carbohydrate units or of at least one particular carbohydrate chain at a particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from CHOdhfr− [ATCC No. 
- sadrži najmanje 20% više nabijenih N-glikozidno vezanih ugljikohidratnih lanaca u ukupnim ugljikohidratnim jedinicama ili u najmanje jednom određenom ugljikohidratnom lancu na određenom mjestu glikoziliranja u molekuli protutijela kod molekula protutijela u navedenom pripravku s molekulom protutijela u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
Disclosed herein is a pharmaceutical composition comprising the hydrobromide described above, and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1-5, te farmaceutski prihvatljiv nosač ili dodatak za otapanje.
pre-B acute lymphocytic leukemia (pediatric indication), adult acute lymphocytic leukemia, mantle cell lymphoma or diffuse large B-cell lymphoma; 
akutna limfocitna leukemija pre-B stanica (pedijatrijska indikacija), adultna akutna limfocitna leukemija, limfom mantle stanica ili difuzni limfom krupnih B stanica;
The process of claim 3, wherein the mixture in step (i) is heated to a temperature of about 30° C. to about 50° C. 
Postupak prema zahtjevu 4, naznačen time, da se smjesa u koraku (i) zagrijava do temperature 30 "C do 50 *C.
The device according to claim 1, wherein the crypto means are used for securely transferring a new generated key from the second integrated circuit (20) to the first integrated circuit (10). 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što se sredstvo za šifriranje upotrebljava za siguran prijenos novog generiranog ključa iz drugog integriranog kruga (20) u prvi integrirani krug (10).
The dry sinsemilla cannabis inflorescence of claim 1 or claim 2, wherein the CBD content is at least 5% by weight, and the THC content is at least 5% by weight. 
Suha inflorescencija besjemenog kanabisa u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što je sadržaj CBD najmanje 5%, težinski, a sadržaj THC je najmanje 5%, težinski.
The apparatus as defined in claim 5 comprising an adhesive application nozzle for discharging the adhesive and means for controlling the temperature of the adhesive. 
Uređaj u skladu s patentnim zahtjevom 5, naznačen time što sadržava mlaznicu za nanošenje ljepljivog materijala koja ispušta ljepljivi materijal i uređaj za reguliranje temperature ljepljivog materijala.
The watermark decoder according to one of claims 9 to 11, wherein the synchronization determinator is configured to compute likelihood measures for a plurality of positional choices of the first and second subset with reference to the time-frequency-domain representation, to obtain a sequence of likelihood measures associated with the different positioned choices of the first and second subset; and wherein the synchronization determinator is configured to correlate the sequence of likelihood measures with a reference sequence, in order to determine a synchronization hit, or to filter the sequence of likelihood measures with a matched filter, adapted to an expected sequence of likelihood values, in order to determine a synchronization hit. 
Dekoder vodenog žiga prema jednom od zahtjeva 9 do 11, naznačen time, da je uređaj za određivanje sinhronizacije konfiguriran da izračuna procjene vjerojatnosti za veći broj izbora položaja prvog i drugog podskupa u odnosu prema prikazu vremena, frekvencije i domene, u svrhu dobivanja niza procjena vjerojatnosti povezanih s različitim izborima položaja prvog i drugog podskupa; 1 pri čemu je uređaj za određivanje sinhronizacije konfiguriran za korelaciju između niza procjena vjerojatnosti i pozivnog niza, kako bi se odredila najbolja pogođena sinhronizacija, ili kako bi se filtrirao niz procjena vjerojatnosti pomoću usklađenog filtera koji je podešen na očekivani niz vrijednosti vjerojatnosti, u svrhu određivanja najbolje pogođene sinhronizacije.
an antisense oligomer which consists of a nucleotide sequence having deletion, substitution, insertion and/or addition of 1 to 5 nucleotides in the nucleotide sequence of SEQ ID NO: 1 or 2, and has an activity to cause skipping of the 51st exon in the human dystrophin gene; an antisense oligomer which has a nucleotide sequence having at least 80% identity with a nucleotide sequence of SEQ ID NO: 1 or 2 and has an activity to cause skipping of the 51st exon in the human dystrophin gene; and 
(b) antisensni oligomer koji se sastoji od nukleotidne sekvence koja ima deleciju, supstituciju, inserciju i/ili adiciju od 1 do 5 nukleotida u nukleotidnoj sekvenci SEQ ID NO: 1 ili 2, ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu; i (c) antisensni oligomer koji ima nukleotidnu sekvencu koja ima najmanje 80% istovjetnosti s nukleotidnom sekvencom SEQ ID NO: 1 ili 2 1 ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu.
performing uplink timing alignment based on the synchronous timing deviation information, in case that, in an uplink asynchronous status, the synchronous timing deviation information is included in the random access response (S02); and 
Sustav radio komunikacije prema zahtjevu 9 ili 10, naznačen time da korak odbacivanja nadalje sadrži, u sinkronom statusu uzlazne veze, ne provođenje usklađivanja vremena uzlazne veze na osnovi informacije o odstupanju vremena sadržane u primljenom odgovoru slučajnog pristupa (S02).
These compounds have the general formula (I): 
1. Spoj s formulom (I):
R12, at each occurrence, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 R10a; R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl; is hydrogen; and 
, svaki put kada je prisutan, je nezavisno izabran između vodika, alkil, alkenil, alkinil, cikloalkil, aril, arilalkil, heterociklil i heterociklilalkil, gdje cikloalkil, aril, arilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-3 R10a;, svaki put kada je prisutan, je nezavisno izabran između vodika, alkil, cikloalkil i aril; je vodik; i